1. Academic Validation
  2. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling

HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling

  • Redox Biol. 2020 Jan;29:101390. doi: 10.1016/j.redox.2019.101390.
Yunjiang Zhou 1 Keke Wang 1 Yang Zhou 1 Tao Li 1 Mengdi Yang 1 Rui Wang 1 Yaxin Chen 1 Mengran Cao 1 Rong Hu 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • 2 State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China. Electronic address: [email protected].
Abstract

The human HEAT repeat-containing protein 1 (HEATR1), consisting of 2144 Amino acids, is a member of the UTP10 family and contains one HEAT repeat at its C-terminal. HEATR1 has been reported to regulate cytotoxic T lymphocytes and rRNA synthesis, while its functions in tumors are poorly understood. Here, we found that HEATR1 competed with Keap1 for binding to p62/sequestosome 1 (SQSTM1), resulted in up-regulation of Keap1, which then inhibited Nrf2 signaling in pancreatic Cancer cells. HEATR1 knockdown enhanced proliferation and gemcitabine resistance of pancreatic Cancer cells. Moreover, HEATR1 deficiency significantly improved xenografts growth and led to gemcitabine resistance in pancreatic Cancer cell-derived xenografts through up-regulating Nrf2 signaling. By analyzing tumor tissue samples from pancreatic Cancer patients, we found that low expression of HEATR1 was closely correlated with poor prognosis and clinicopathological features. Collectively, we suggest that HEATR1 deficiency promotes proliferation and gemcitabine resistance of pancreatic Cancer through up-regulating Nrf2 signaling, indicating that HEATR1 may be a promising therapeutic target for pancreatic Cancer.

Keywords

Gemcitabine resistance; HEATR1; Nrf2; Pancreatic cancer.

Figures
Products